Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- MDXG +7.9%, PNC +0.5%
Other news:
- CLIR +37.5% (receives order from supermajor oil company to qualify Duplex technology)
- CGI +14.9% (appoints Paul Svindland as CEO effective on or about July 24; Michael Miller, current lead independent director, to become Chairman)
- CTIC +11.2% (announces that European Medicines Agency has validated the Marketing Authorization Application for pacritinib for the treatment of patients with myelofibrosis who have thrombocytopenia)
- BLFS +10.2% (announces that Kolon Life Science, TissueGene's exclusive licensee for Asia, including Korea, has received marketing approval for Invossa-K Inj for degenerative arthritis from the Korea Ministry of Food and Drug Safety)
- HPJ +8.7% (enters smart vacuum market with two new partnerships ),
- GMO +3.7% (FDA has granted Fast Track designation to SB-318 and SB-913, the Co's clinical stage in vivo genome editing product candidates for the treatment of Mucopolysaccharidosis Type I and MPS II)
- ALDR +2.9% (favorable commentary on Thursday's Mad Money),
- MYL +1.9% (Oncologic Drugs Advisory Committee votes unanimously to recommend MYL-1401O -- proposed biosimilar to Genentech's RHHBY unit HERCEPTIN)
- AZN +1.4% (following late sell-off on potential CEO departure announcement)
- MRSN +1.4% (Pfizer discloses 9.8% passive stake)
- GNW +1.2% (Genworth Financial and Oceanwide provide CFIUS update; timing of regulatory reviews will likely delay the completion of the transaction to later than the originally targeted time frame )
- MNK +0.9% (Phase 3 terlipressin trial achieves its enrollment target ahead of schedule - marks halfway point toward interim analysis of trial data), .
Analyst comments:
- NTNX +9% (added to its Conviction Buy list at Goldman)
- AFMD +4.2% (initiated with Buy at Suntrust)
- ULTA +2.3% (upgraded and added to Conviction Buy List at Goldman)
- EXEL +1.9% (initiated with Buy at Suntrust)
- WMT +1.6% (upgraded and added to Conviction Buy List at Goldman)
- ROST +1.1% (upgraded to Outperform at Telsey Advisory Group)
- BA +0.8% (upgraded to Overweight from Neutral at JP Morgan)